|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Partensky C and Bray F: More
deaths from pancreatic cancer than breast cancer in the EU by 2017.
Acta oncol. 55:1158–1160. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miyoshi N, Wagatsuma H, Wakana S,
Shiroishi T, Nomura M, Aisaka K, Kohda T, Surani MA, Kaneko-Ishino
T and Ishino F: Identification of an imprinted gene, Meg3/Gtl2 and
its human homologue MEG3, first mapped on mouse distal chromosome
12 and human chromosome 14q. Genes cells. 5:211–220. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang X, Zhou Y, Mehta KR, Danila DC,
Scolavino S, Johnson SR and Klibanski A: A pituitary-derived MEG3
isoform functions as a growth suppressor in tumor cells. J Clin
Endocrinol Metab. 88:5119–5126. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheng R, Lo K, Huang D and Tsao S: Loss of
heterozygosity on chromosome 14 in primary nasopharyngeal
carcinoma. Int J Oncol. 10:1047–1050. 1997.PubMed/NCBI
|
|
6
|
Liu J, Wan L, Lu K, Sun M, Pan X, Zhang P,
Lu B, Liu G and Wang Z: The long noncoding RNA MEG3 contributes to
cisplatin resistance of human lung adenocarcinoma. PLoS One.
10:e1145862015.
|
|
7
|
Bando T, Kato Y, Ihara Y, Yamagishi F,
Tsukada K and Isobe M: Loss of heterozygosity of 14q32 in
colorectal carcinoma. Cancer Genet Cytogenet. 111:161–165. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH
and Guo RH: Decreased expression of long noncoding RNA MEG3 affects
cell proliferation and predicts a poor prognosis in patients with
colorectal cancer. Tumour Biol. 36:4851–4859. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Braconi C, Kogure T, Valeri N, Huang N,
Nuovo G, Costinean S, Negrini M, Miotto E, Croce CM and Patel T:
MicroRNA-29 can regulate expression of the long non-coding RNA gene
MEG3 in hepatocellular. cancer. 30:1–4766. 2011.
|
|
10
|
Greife A, Knievel J, Ribarska T, Niegisch
G and Schulz WA: Concomitant downregulation of the imprinted genes
DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial
carcinoma. Clin Epigenetics. 6:292014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tian ZZ, Guo XJ, Zhao YM and Fang Y:
Decreased expression of long non-coding RNA MEG3 acts as a
potential predictor biomarker in progression and poor prognosis of
osteosarcoma. Int J Clin Exp Pathol. 8:15138–15142. 2015.PubMed/NCBI
|
|
12
|
Itoyama T, Chaganti RS, Yamada Y,
Tsukasaki K, Atogami S, Nakamura H, Tomonaga M, Ohshima K, Kikuchi
M and Sadamori N: Cytogenetic analysis and clinical significance in
adult T-cell leukemia/lymphoma: A study of 50 cases from the human
T-cell leukemia virus type-1 endemic area, Nagasaki. Blood.
97:3612–3620. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huarte M, Guttman M, Feldser D, Garber M,
Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M,
et al: A large intergenic noncoding RNA induced by p53 mediates
global gene repression in the p53 response. Cell. 142:409–419.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao J, Zhang X, Zhou Y, Ansell PJ and
Klibanski A: Cyclic AMP stimulates MEG3 gene expression in cells
through a cAMP-response element (CRE) in the MEG3 proximal promoter
region. Int J Biochem Cell Biol. 38:1808–1820. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gordon FE, Nutt CL, Cheunsuchon P,
Nakayama Y, Provencher KA, Rice KA, Zhou Y, Zhang X and Klibanski
A: Increased expression of angiogenic genes in the brains of mouse
meg3-null embryos. Endocrinology. 151:2443–2452. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao Y and Lu X: Decreased expression of
MEG3 contributes to retinoblastoma progression and affects
retinoblastoma cell growth by regulating the activity of
Wnt/β-catenin pathway. Tumour Biol. 37:1461–1469. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang L, Wang G, Jia T, Zhang L, Li Y, Han
Y, Zhang K, Lin G, Zhang R, Li J and Wang L: Armored long
non-coding RNA MEG3 targeting EGFR based on recombinant MS2
bacteriophage virus-like particles against hepatocellular
carcinoma. Oncotarget. 7:23988–24004. 2016.PubMed/NCBI
|
|
18
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hollier BG, Evans K and Mani SA: The
epithelial-to-mesenchymal transition and cancer stem cells: A
coalition against cancer therapies. J Mammary Gland Biol Neoplasia.
14:29–43. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shah AN, Summy JM, Zhang J, Park SI,
Parikh NU and Gallick GE: Development and characterization of
gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol.
14:3629–3637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A,
Azmi AS, Ali S, Abbruzzese JL, Gallick GE and Sarkar FH:
Acquisition of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Izumiya M, Kabashima A, Higuchi H,
Igarashi T, Sakai G, Iizuka H, Nakamura S, Adachi M, Hamamoto Y,
Funakoshi S, et al: Chemoresistance is associated with cancer stem
cell-like properties and epithelial-to-mesenchymal transition in
pancreatic cancer cells. Anticancer Res. 32:3847–3853.
2012.PubMed/NCBI
|
